



# Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues

Samuel C. R. Sherratt<sup>1,2</sup> · Peter Libby<sup>3</sup> · Matthew J. Budoff<sup>4</sup> · Deepak L. Bhatt<sup>5</sup> · R. Preston Mason<sup>2,3</sup>

Accepted: 15 October 2022 / Published online: 29 December 2022  
© The Author(s) 2022

## Abstract

**Purpose of Review** The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce residual cardiovascular (CV) risk among statin-treated subjects. The outcome trials have yielded highly inconsistent results, perhaps attributable to variations in dosage, formulation, and composition. In particular, CV trials using icosapent ethyl (IPE), a highly purified ethyl ester of EPA, reproducibly reduced CV events and progression of atherosclerosis compared with mixed EPA/DHA treatments. This review summarizes the mechanistic evidence for differences among n3-FAs on the development and manifestations of atherothrombotic disease.

**Recent Findings** Large randomized clinical trials with n3-FAs have produced discordant outcomes despite similar patient profiles, doses, and triglyceride (TG)-lowering effects. A large, randomized trial with IPE, a prescription EPA only formulation, showed robust reduction in CV events in statin treated patients in a manner proportional to achieved blood EPA concentrations. Multiple trials using mixed EPA/DHA formulations have not shown such benefits, despite similar TG lowering. These inconsistencies have inspired investigations into mechanistic differences among n3-FAs, as EPA and DHA have distinct membrane interactions, metabolic products, effects on cholesterol efflux, antioxidant properties, and tissue distribution. EPA maintains normal membrane cholesterol distribution, enhances endothelial function, and in combination with statins improves features implicated in plaque stability and reduces lipid content of plaques.

**Summary** Insights into reductions in residual CV risk have emerged from clinical trials using different formulations of n3-FAs. Among high-risk patients on contemporary care, mixed n3-FA formulations showed no reduction in CV events. The distinct benefits of IPE in multiple trials may arise from pleiotropic actions that correlate with on-treatment EPA levels beyond TG-lowering. These effects include altered platelet function, inflammation, cholesterol distribution, and endothelial dysfunction. Elucidating such mechanisms of vascular protection for EPA may lead to new interventions for atherosclerosis, a disease that continues to expand worldwide.

**Keywords** Atherosclerosis · Triglycerides · Lipoproteins · Omega-3 fatty acids · Cholesterol · Eicosapentaenoic acid

✉ R. Preston Mason  
rpmason@elucidaresearch.com

- <sup>1</sup> Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH 03823, USA
- <sup>2</sup> Elucida Research LLC, P.O. Box 7100, Beverly, MA 01915-0091, USA
- <sup>3</sup> Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115-6110, USA
- <sup>4</sup> Department of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA
- <sup>5</sup> Mount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, New York, NY, USA

## Introduction

According to the World Health Organization (WHO), atherothrombotic cardiovascular (CV) disease has become the leading cause of global mortality with a disproportionate impact on low and middle income countries [1]. Despite effective control of low-density lipoproteins (LDL) with oral and non-oral interventions, CV risk persists, likely due in part to elevated triglyceride (TG)-rich lipoproteins (TGRLs), a dyslipidemia particularly prevalent in patients with diabetes and metabolic disease [2, 3, 4•]. Genetic and epidemiologic analyses support an independent role for TGRLs as a risk factor and strong contributor to overall mortality [5, 6, 7••, 8]. TGRL concentrations associate with increased CV

risk and their accompanying proteins like apolipoprotein C3 (ApoC3) and angiopoietin-like 3 (ANGPTL3) which limit lipoprotein lipase (LPL) activity, leading to a rise in TGRL levels. Human mendelian randomization studies strongly support the causality of TGRL in atherosclerotic events, but such studies cannot on their own determine the independence of TGs as a risk factor as variants often have pleiotropic effects that may influence disease etiology [9, 10]. Indeed, TGRL incite inflammation to much greater degree than LDL-C particles, and thus, elevated TGRL may contribute to the inflammatory component of residual risk [11]. Furthermore, agents that effectively lower TGs, including potent fibrate derivatives, have failed to reduce CV events risk in high-risk patients when receiving contemporary care. These findings have engendered debate about the relative atherogenicity of LDL-C cholesterol, measured as apolipoprotein B (ApoB), versus TGs in lipoprotein particles.

Randomized CV trials have tested n3-FAs for residual risk reduction in patients with well-controlled LDL-C levels and elevated TGs. Despite similar and effective TG reductions, the results of these trials have been highly inconsistent. Sufficiently powered outcome trials have demonstrated benefits of an ethyl ester formulation of eicosapentaenoic acid (EPA) known as icosapent ethyl (IPE), but not of more traditional, mixed n3-FA preparations or other TG-lowering agents [12, 13]. These findings have piqued interest in the mechanistic effects of different n3-FA formulations, and especially IPE, in relation to reductions in atherothrombotic risk. In vivo and in vitro studies indicate that EPA has distinct metabolic products, plaque incorporation, membrane interactions, lipid antioxidant activity, and tissue distribution (i.e., arterial) compared to other n3-FAs, especially DHA that concentrates in neuronal membranes [7••, 14]. EPA maintains cholesterol distribution in membranes and preserves normal phospholipid packing constraints, competes with arachidonic acid for cyclooxygenase (COX), and enhances endothelial function in combination with a high intensity statin as compared to DHA [15]. These distinct biological actions for EPA, along with its complex bioactive metabolites, may lead to new insights into mechanisms of atherothrombotic disease and therapeutic interventions.

## Rationale for TG-Lowering and Reduced Residual Risk

Plasma TGs are carried in chylomicrons, VLDLs, and remnant particles, collectively termed TGRLs, and independently predict ischemic events and all-cause mortality [8, 16, 17]. The TGRLs essentially carry all the plasma cholesterol not associated with either LDL-C or HDL in circulation. Data from the Copenhagen General Population Study indicate that elevations in TGs are common in


developed countries as over 25% of individuals had TG levels > 176 mg/dL while 21% had remnant cholesterol > 39 mg/dL [8]. Observational studies indicate that individuals with non-fasting TGs of 580 mg/dL have > threefold higher risk for ischemic stroke compared with individuals with levels of 70 mg/dL. Such TG elevations confer a greater than fivefold increased risk for myocardial infarction (MI) and twofold increase in the risk for all-cause mortality that correlated with higher TGRLs.

What mechanisms account for the atherogenicity of TGRLs? Due to their large size, TGRLs do not efficiently penetrate the endothelial layer compared to other lipoprotein particles like LDL. However, smaller “remnant” particles formed from TGRLs during enzymatic catabolism are rich in cholesterol and highly atherogenic. Reduced activity of various lipases that facilitate TGRL catabolism results in excessive remnant formation and increased disease progression. A protein associated with TGRLs, ApoC3, inhibits lipase activity and also associates with increased CV risk [18]. Lipase activity is also inhibited by ANGPTL3 and ANGPTL4 associated with the surface of endothelial cells. These observations have led to new TG-lowering therapies strategies that affect the expression and/or activity of these proteins.

In the recent TRANSLATE-TIMI 70 trial, the ANGPTL3-targeted antisense oligonucleotide vupanorsen reduced TGs in patients with hypertriglyceridemia by more than half compared with placebo [19]. However, the vupanorsen clinical program halted over concerns about efficacy and certain side effects, including liver steatosis [20]. A monoclonal antibody (evinacumab) approach directed against ANGPTL3 effectively reduced LDL-C in patients with homozygous familial hypercholesterolemia and refractory hypercholesterolemia [21, 22]. The antisense oligonucleotide volanesorsen, which decreases ApoC3 expression, has also shown robust TG lowering (77%) in patients with familial chylomicronemia syndrome compared with placebo, but it remains to be seen whether this effect will reduce events in patients with established CV disease risk. [23]

The smaller, atherogenic remnants of TGRLs cross the endothelial layer more efficiently than the larger forms. Within the plaque they promote atherosclerosis and add to the cholesterol content of the lesion. Macrophages efficiently engulf the internalized TGRL remnants to promote foam cell formation in the arterial intima due to their cholesterol content and dependence on internalization by the classical LDL-C receptor. This receptor's expression falls as intracellular cholesterol rises, rendering foam cell formation difficult by LDL-C loading alone (Fig. 1). As a result, the cholesterol in lesions may depend more on remnants than on other ApoB containing lipoproteins like LDL. The fatty acids associated with TGRLs, particularly saturated fats like palmitate, can activate the NLRP3 (NLR family pyrin domain-containing)

**Fig. 1** Atherosclerotic plaque initiation and progression—the nexus of lipid accumulation and inflammation. Atherosclerosis is a complex inflammatory response at the nexus of endothelial cell dysfunction, leukocyte activation, lipid accumulation and altered smooth muscle cells functions. If not interrupted, these integrated cellular processes culminate in plaque disruption and formation of an occlusive thrombus



inflammasome which, in turn, produces activated forms of the proinflammatory cytokines IL (interleukin)-1 $\beta$  and IL-18 [24]. NLRP3, once activated by various danger signals, recruits the adapted apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD) (ASC). This converts procaspase-1 into caspase-1. The caspase-1 then converts the inactive pro-forms of interleukins (IL)-1 $\beta$  and IL-18 to their mature functional forms for subsequent release from cells [25, 26]. There appear to be several mechanisms of activation for the NLRP3 inflammasome depending on the inflammatory stimulus. Animals deficient in the expression of the NLRP3 inflammasome or cathepsin molecules are unable to mount an inflammatory response to a number of atherogenic stimuli, including cholesterol crystals. [27•]

TGRLs exert direct proinflammatory effects in concert with ApoC3 on macrophages and endothelial cells. The causality of ApoC3 in atherothrombosis is supported by a number of human genetic studies [18]. Rare loss of function mutations that reduce ApoC3 activity were associated with lower risk of CV disease and circulating TGs. Thus, certain protective effects of n3-FAs on atherothrombosis may be due to inhibiting the proinflammatory effects of accumulated TGRLs in concert with reduced ApoC3 levels. [28]

Despite broad epidemiological and genetic evidence associated with elevated TGs and CV risk, clinical trials using TG-lowering agents (e.g., fibrate derivatives, niacin) have failed to reduce such risk [29–31]. Indeed, the extent of TG

lowering did not predict changes in CV events in these or other trials using n3-FAs in patients on contemporary care that include statins [13]. These results suggest that the TG content in TGRLs does not causally add to CV risk, rather the cholesterol in these particles may drive their atherogenicity. Indeed, variants associated with these particles suggest that changes in ApoB absolute levels were the best predictor of CV event reduction after controlling for other variables using mendelian randomization analyses [10]. Thus, TG-lowering itself may not provide incremental protection for high risk patients who receive sufficient LDL-C lowering therapy. [12, 13]

A trial was conducted using a fenofibrate derivative known as a selective peroxisome proliferator-activated receptor alpha modulator (SPPARM- $\alpha$ ). This compound, pemafibrate, was selected as it has greater affinity and specificity for PPAR- $\alpha$  by more than 2000-fold compared to either PPAR- $\gamma$  or - $\delta$  (delta). After promising phase 2 trials, The Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial prospectively enrolled patients with elevated TGs as subgroups of such patients had previously showed the greatest potential for benefit with effective TG-lowering agents [32]. The primary objective of this phase 3 study was to test the ability of pemafibrate (0.2 mg bid) to delay the time of the first occurrence of nonfatal myocardial infarction (MI), nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, and CV

death in statin treated patients with diabetes and moderate hypertriglyceridemia (fasting TGs:  $\geq 200$  to  $< 500$  mg/dL; HDL-C  $\leq 40$  mg/dL). PROMINENT was terminated early in these high risk patients due to futility following the recommendation of the independent data-monitoring committee [33]. Thus, TG-lowering agents from different classes and potency have consistently failed to reduce CV risk on top of high intensity statins despite effective TG lowering. [29–31]

## The n3-FAs Reduce TGs Through Various Mechanisms

The n3-FAs effectively lower TGs in a dose-dependent manner by enhanced fatty acid oxidation as well as blockade of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT), resulting in attenuated hepatic VLDL production and lipogenesis [34, 35]. The n3-FAs specifically stimulate the G-protein coupled receptor GPR120, promoting brown and beige adipocyte differentiation, thus producing thermogenic activation [36–38]. GPR120 binding also causes the release of fibroblast growth factor-21 (FGF21) by adipocytes. FGF21 knock out in mice impairs GPR120-mediated adipocyte activation and browning. Thus, GPR120 activates adipocytes by a mechanism that involves induction of FGF21 following stimulation with n3-FAs. [37]

EPA and other n3-FAs like DHA are also especially effective fatty acid agonists of PPARs [39]. PPARs are part of the nuclear hormone receptor family and represent a subgroup of three ligand-inducible transcription factors. Three different isoforms of PPARs have been described so far in mammals: PPAR- $\alpha$ , PPAR- $\beta/\delta$  and PPAR- $\gamma$ . These are part of a nuclear hormone receptor superfamily and, by binding to PPAR-responsive regulatory elements (PPRE), heterodimerize with the retinoid X receptor (RXR). This binding leads to formation of an active transcriptional complex that regulates various genes involved in lipid metabolism. This activated complex also regulates various aspects of adipogenesis, inflammation and metabolic homeostasis [40]. PPAR- $\alpha$  activation reduces VLDL and TG levels while increasing circulating high density lipoprotein (HDL) levels following induction of hepatic apolipoprotein A-I and apolipoprotein A-II expression. Fibrates (PPAR $\alpha$  agonists) lower circulating TG levels while glitazones (PPAR- $\gamma$  agonists) induce lipoprotein lipase expression in adipose tissue. [41]

Circulating TGs correlate strongly with plasma apolipoprotein levels in patients with hypertriglyceridemia. In the MARINE and ANCHOR trials, IPE treatment decreased levels of ApoC3 levels along with TGs, resulting in improved LPL activity and endocytosis of ApoB particles [28]. Certain n3-FA derived N-acyl taurines (NATs) also inhibit TG hydrolysis and absorption in enterocytes from animals fed a high fat diet [42]. Thus, the multiple mechanism(s) of

TG-lowering for IPE include changes in lipogenesis, beta oxidation, lipase activity and gene expression.

## High-Dose EPA Treatment and Residual Cardiovascular Risk

In contrast to previous TG-lowering trials, IPE reduced a composite of CV disease events in such patients with elevated TGs. REDUCE-IT investigated the effects of IPE on residual CV disease risk in statin treated patients [43••]. The trial randomized over 8,000 patients with elevated TGs ( $\geq 135$  and  $< 499$  mg/dL) and established CV disease or diabetes with at least one additional risk factor to 4 g/d IPE or mineral oil placebo. This multicenter, placebo-controlled trial enrolled approximately 71% of the participants based on secondary CV prevention while the remaining subjects (29%) had diabetes and at least one other risk factor. The primary endpoint was a 5-point composite MACE (CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, and coronary revascularization). REDUCE-IT showed a 25% relative risk reduction (HR: 0.75, 95% confidence interval (CI): 0.68–0.83,  $P < 0.001$ ) and 4.8% (95% CI: 3.1–6.5) absolute risk reduction of the primary endpoint with a number needed to treat (NNT) of 21.

At the first prespecified interim analysis, the Data Safety Monitoring Board for REDUCE-IT detected a risk reduction of the primary endpoint with IPE (HR: 0.77, 95% CI: 0.68–0.87,  $P < 0.001$ ) after approximated 60% expected events had occurred. This reduction in events achieved significance after approximately 21 months following randomization, indicating an early benefit with IPE treatment [44]. Prespecified hierarchical analysis of endpoints showed that IPE treatment lowered risk of fatal or non-fatal MI by 31% ( $P < 0.001$ ), fatal or non-fatal stroke by 28% ( $P = 0.01$ ), and CV death by 20% ( $P = 0.03$ ). Total ischemic events (first and subsequent) fell by 30% ( $P < 0.001$ ) in the IPE treatment arm, and first coronary revascularizations declined by 34% ( $P < 0.001$ ) [45, 46]. Both post hoc and prespecified subgroup analyses revealed consistent event risk reduction with IPE regardless of CV disease history, including patients with prior MI (26%,  $P < 0.001$ ), prior percutaneous coronary intervention (PCI, 34%,  $P < 0.001$ ), prior coronary artery bypass graft (CABG, 24%,  $P = 0.004$ ), or with varying kidney function based on estimated glomerular filtration rate (eGFR,  $< 60$  mL/min (29%,  $P < 0.001$ ),  $\geq 60$  and  $< 90$  mL/min (20%,  $P = 0.001$ ), and  $\geq 90$  mL/min (30%,  $P = 0.003$ ). [47–50]

Additionally, although all patients were enrolled based on adherence to statin therapy, the risk reduction with IPE did not differ based on the type of statin (lipophilic or lipophobic) the patients received [51]. Finally, there was a 31% relative risk reduction in the primary composite endpoint

in the 3,146 patients enrolled in the USA ( $P < 0.001$ ) [52]. Importantly, despite the baseline TG threshold required for enrollment in REDUCE-IT, IPE conferred a consistent risk reduction regardless of baseline or achieved TG levels, indicating that TG lowering itself does not explain the mechanism of event reduction in IPE-treated patients. [43••]

IPE treatment was associated with more serious adverse events in REDUCE-IT but similar to placebo. In particular, there were increased events related to hospitalization for atrial fibrillation (3.1% for EPA vs 2.1% for placebo,  $P = 0.004$ ) [43••]. However, this was not clinically significant as there were substantially lower rates of stroke with IPE (28% reduction in fatal or non-fatal stroke,  $P = 0.01$ ). Bleeding rates overall were also low but slightly higher in subjects treated with IPE (2.7% vs 2.1%,  $p = 0.06$ ), with no fatal bleeding events related to study drug. There was also no significant increase in gastrointestinal bleeding or hemorrhagic stroke events in adjudicated cases.

Favorable outcomes with IPE were also reported in the Japan EPA Lipid Intervention Study (JELIS) trial. JELIS enrolled subjects with hypercholesterolemia but not a pre-specified minimum TG level [53•]. This was an open label trial where 18,645 patients were randomized to IPE (1.8 g/d) on top of a statin. IPE treatment was associated with a 19% ( $p = 0.011$ ) reduction in CV events compared to subjects administered statin alone. The population in the JELIS study included both primary and secondary prevention participants. The median plasma TG levels of the participants at baseline (153 mg/dL) were close to normal and TG levels fell only 9% overall, compared to baseline with IPE treatment. Again, TG lowering with IPE treatment did not predict event reduction as observed in REDUCE-IT. A post hoc review in JELIS subjects with elevated TG levels ( $> 150$  mg/dl) at baseline along with low HDL-C levels ( $< 40$  mg/dl) showed a 53% reduction ( $p = 0.043$ ) in events with IPE treatment. [54]

## High-Dose EPA and Progression of Atherosclerosis in Patients with Elevated TGs

The benefits with IPE beyond TG lowering may indicate direct effects of EPA on progression of atherosclerosis not reproduced with low dose or mixed n3-FA preparations that include DHA in the formulation [12, 13]. Indeed, the best predictor for outcomes with IPE in REDUCE-IT was blood EPA concentrations as compared with other biomarkers of CV risk [55]. Imaging studies indicate that EPA has direct effects on plaque progression in patients with coronary artery disease. Integrated backscatter intravascular ultrasound (IB-IVUS) was used to measure changes in coronary thin-cap fibroatheroma in IPE treated patients versus statin

alone in the Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression Evaluated by Integrated Backscatter Intravascular Ultrasonography (CHERRY) trial [56]. The IPE plus statin intervention was associated with a significant reduction in plaque volume concomitant with a decrease in the AA-EPA ratio compared with statin alone. A similar randomized trial of IPE plus statin versus statin alone found a significant increase in fibrous cap thickness with IPE plus statin therapy versus statin therapy alone using optical computed tomography (OCT). [57]

The randomized Effect of Vascepa on Improving Coronary Atherosclerosis in People with High Triglycerides Taking Statin Therapy (EVAPORATE) trial used multidetector computed tomography to measure the effects of IPE in statin-treated patients having coronary disease and dyslipidemia compared to statin alone [58•]. IPE (4 g/day) treatment for 18 months correlated with reduced low attenuation plaque (LAP) volume by 17% compared with baseline. This may be particularly important in explaining the reductions of MI with IPE, as patients with a LAP burden of more than 4% are more likely to experience an MI [59]. Plaque regression with intervention in EVAPORATE was consistent in several measurements of plaque volume including total plaque. Changes in vulnerable plaque characteristics with IPE treatment was not associated with TG or other lipid changes. The benefits of IPE were observed even after multivariable adjustment for risk factors of CV. [58•]

These changes in plaque volume and fibrous cap thickness with IPE treatment correlate with changes in the cellular content of plaque. The n3-FAs, along with their various metabolites, differentially associated with lipid-rich plaques in atherosclerosis prone animals. In ApoE-deficient mice fed a Western diet, mass spectrometry measured the plaque distribution of n3-FAs and their metabolites, in conjunction with histological analysis [60•]. Along with a common metabolite, 12-hydroxy-EPA, EPA was associated with thin-cap plaques and an increase in M2 macrophages. A concentration gradient for EPA that extended from the endothelium to the media was also observed in the aortic arch. Remarkably, DHA associated randomly with both thin- and thick-cap plaques while not affecting intima-media thickness; EPA, by contrast, significantly reduced plaque thickness.

Additional insights into the arterial distribution of EPA versus DHA came from carotid endarterectomy studies in patients administered a short-term intervention of mixed formulation n3-FAs [61]. Once again, a preferential association of EPA but not DHA with lipid rich lesions was observed in the endarterectomy. There was also an inverse correlation between indicators of plaque instability, T cell number and overall inflammation with the amount of phospholipid-containing EPA. EPA incorporated into atherosclerotic lesions where it modified indices of tissue inflammation, including T cell content as well as foam cells. Collectively, these

results show consistent effects on plaque stability with EPA to a greater extent than other n3-FAs like DHA. These findings may help explain the broad effects of IPE treatment on atherothrombotic-related event risk reduction in large clinical trials.

### Mixed Omega-3 Fatty Acid Treatments and Residual Cardiovascular Risk

At the same or lower doses, mixed n3-FA formulations containing EPA and DHA have not reproduced the clinical benefits of IPE reported in large outcome trials. The Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) trial evaluated the effects of a carboxylic acid formulation of EPA and DHA (4 g/d) in 13,078 patients with elevated TGs and CV disease risk including diabetes, quite similar to the REDUCE-IT population [62•]. Similar to previous mixed n3-FA formulations, this well-conducted trial did not show any reduction in risk of CV events. The STRENGTH trial was thus halted prematurely despite a 19% reduction in TG levels. This result, along with other trials discussed below, raises questions about possible distinct biological effects of DHA that counter the beneficial effects of EPA.

The null findings from STRENGTH were consistent with the Study of Cardiovascular Events in Diabetes (ASCEND) trial investigating the effects of n3-FA supplementation for primary prevention of CV events in patients with diabetes [63]. Specifically, this trial tested mixed EPA/DHA at the lower dose of 1 g/d on the incidence of serious vascular events in over 15,000 patients with diabetes but not atherosclerotic disease and, importantly, without a statin adherence requirement. There was no reduction in first serious vascular events among subjects randomized to treatment. Similarly, The Vitamin D and Omega-3 Trial (VITAL) tested a mixed n3-FA formulation at 1 g/d (and vitamin D<sub>3</sub> at 2,000 IU/d) in close to 26,000 patients, including more than 5,000 black patients, for primary prevention of CV events and invasive cancer [64]. Again, neither the composite CV endpoint nor cancer-associated endpoint fell significantly. Thus, STRENGTH, ASCEND and VITAL showed no benefit in either primary and secondary CV populations using various mixed EPA/DHA formulations and doses. Several meta-analyses cast further doubt on the benefits of mixed n3-FA formulations for CV risk reduction, routinely showing no significant reduction of major CV events. [65•, 66–68]

Blood levels of EPA emerged as the best predictor of clinical benefit in trials using IPE such as JELIS and REDUCE-IT [55]. Remarkably, a similar relationship was not reported in trials that used mixed n3-FA formulations, including STRENGTH, despite the highest tertile of achieved

plasma EPA levels (151 µg/mL) reaching similar levels to the median serum EPA levels in REDUCE-IT (144 µg/mL) [69]. Part of the explanation may be that changes in EPA always associated with concomitant increases in DHA (median for highest tertile of achieved plasma DHA levels in STRENGTH was 118 µg/mL), a fatty acid that competes with EPA for similar enzymatic pathways and has nearly opposite effects on membrane interactions and cholesterol distribution [70]. In the OMEga-3 fatty acids in Elderly with Myocardial Infarction (OMEMI) trial, an EPA/DHA prescription formulation (1.8 g/d) was tested in patients with a recent acute MI [71]. The EPA/DHA treatment did not reduce the primary endpoint of CV events even as median EPA (87%) levels increased. In this trial, the increase in EPA was again accompanied by a significant increase in serum levels of DHA (16%) [71, 72]. A minimum or threshold level of EPA may be required for meaningful CV risk reduction in outcome trials using n3-FAs. In STRENGTH, the overall median on-treatment EPA levels were low, even as compared with the baseline levels of measured in the JELIS trial (89.6 vs. 97 µg/mL, respectively), and were 40% less than in subjects enrolled in REDUCE-IT [7••, 70]. Additionally, the chemical form of the fatty acids in each formulation may contribute to differences in absorption, distribution and ultimately clinical outcomes (ethyl ester in REDUCE-IT, carboxylic acid in STRENGTH), though this requires further investigation.

It has been argued that the CV benefit with IPE in certain trials (most notably REDUCE-IT) related to the use of pharmaceutical grade mineral oil as comparator. Some posit that mineral oil may increase CV risk directly or indirectly by altering metabolism of other drugs even at the dose used in REDUCE-IT (2 g bid), which was almost tenfold less than the amount used in treatment of constipation (30–90 g). A post hoc analysis of REDUCE-IT showed that LDL-C, IL-1β, and hsCRP levels increased significantly in the placebo arm at 12 months compared with baseline (hsCRP 2.8 mg/L vs. 1.8 mg/L; LDL-C 96 mg/dL vs 87 mg/dL; IL-1β 0.06 pg/mL vs 0.08 pg/mL) [43••, 73]. While these changes were statistically significant, it is unclear if they convey clinical significance to such a degree as to negate the benefits of IPE in clinical trials. When placed in context with other CVOTs, the changes in inflammatory biomarkers appear negligible. For example, the baseline hsCRP levels in the JUPITER trial were almost double the baseline levels in REDUCE-IT (4.3 vs 2.2 mg/dL), and baseline IL-1β levels in the CIRT trial were more than 24-times greater than baseline levels in REDUCE-IT (1.46 vs 0.06 pg/mL) [74, 75]. Based on these values, it is clear that the patient population in REDUCE-IT was distinct from those in other CVOTs recruiting for anti-inflammatory treatments, and thus, not surprising that event reduction with IPE did not

correlate with reductions in these markers. Additionally, if mineral oil were causing pro-inflammatory effects to an extent that would artificially indicate event reduction with IPE, one might expect that the inflammatory biomarkers would continue to increase with continuous administration. However, the hsCRP and IL-1 $\beta$  levels in the placebo arm do not significantly increase after 12 months through the end of the observation period. To adequately determine if the mechanism of action of IPE involves the IL-1-IL-6-hsCRP axis, a prospective, randomized controlled trial that recruits patients based on elevated hsCRP levels would be required. Additionally, a comprehensive review of mineral oil use in CV trials found no reproducible, consistently statistically significant effect of mineral oil on inflammatory markers, including hsCRP, or lipid levels, challenging a mechanistic argument that mineral oil contributed to these biomarker changes. [76]

It has also been proposed that mineral oil, despite very low oral absorption, interferes with the pharmacokinetics of statins, leading to reduced potency and LDL-C reductions. Animal experiments tested this conjecture directly with lipophilic and hydrophilic statins, including atorvastatin and pravastatin, respectively. [77] Administered levels of mineral oil that reproduced REDUCE-IT resulted in no change in the absorption and bioavailability of these statins compared with water placebo. Indeed, there was also no difference in beneficial outcomes among patients in REDUCE-IT being administered either lipophilic or hydrophilic statins [77]. One would expect mineral oil to introduce a bias against certain hydrophobic statins based on their affinity to oil, but this was not observed in either laboratory animals or in REDUCE-IT. They also measured and found that typical inflammatory markers were not affected on days 10 and 22 in repeat daily dosing groups that received atorvastatin in the absence and presence of mineral oil, including plasma levels of IL-5, IL-6, IL-10, and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ). There were also no significant differences in the mean number of T cells, macrophages or B cells in either the small intestine or colon after repeat dosing of atorvastatin with or without mineral oil co-administration.

Post hoc analyses performed independently by the FDA demonstrated that the benefits of IPE were not influenced by changes in LDL-C levels in subjects randomized to mineral oil or with increases in hsCRP [76, 78]. Several other biomarkers that correlate with LDL-C and hsCRP showed similar patterns, though in many cases, the changes were large on a relative scale, but small on an absolute scale and many were below the lower level of quantification of the assays [73]. The FDA thus concluded that the choice of placebo would have minimal impact, if any, on the clinical outcomes in REDUCE-IT [76, 78]. Finally, computed tomography analysis of the effects of mineral oil on total and non-calcified plaque volume showed no differences in

progression from baseline as compared to non-mineral oil comparators consisting of cellulose. [79]

## Do Fish Oil Supplements Have a Role in Reducing Cardiovascular Disease?

The n3-FAs EPA and DHA must be obtained through the diet as humans lack the necessary enzyme for adding the  $\omega$ -3 double bond ( $\Delta$ 15 desaturase) to long chain fatty acids [80]. Dietary sources of n3-FAs include marine oily fish that, in turn, obtain these oils through their consumption of marine algae and plankton. Additionally, there are plant sources for  $\alpha$ -linolenic acid (ALA, 18:3 n-3), a precursor to the more unsaturated and longer chained EPA and DHA. ALA can be obtained from the oil of various plant seeds and nuts including flaxseed, chia, walnuts and echium seeds [81]. Only a small percentage of ALA is converted by humans to EPA or DHA, except among pre-menopausal women where elevated estrogen levels promote the conversion of ALA to DHA, a fatty acid necessary for fetal development. [82–84]

Levels of n3-FAs vary widely among fish species depending on their diets and metabolism. Marine species like mackerel or salmon have up to 4 g per serving as compared with less oily white fish. For instance, tilapia has tenfold less tissue levels of n3-FAs while instead enriched with n6-FAs [85]. Even in fish typically rich in n3-FAs, these levels will decrease if natural sources of algae are replaced by commercial food sources including vegetable-based grains that contain n6-FAs (e.g., linoleic acid) [86, 87]. Thus, fish consumption alone may not provide adequate n3-FA content to elicit the benefits for CV health. Another popular option for patients to increase n3-FA intake is fish oil dietary supplements (FODS) and krill oil supplements [88]. These contain sources of n3-FAs primarily in the form of TGs as found in the tissue of most marine species, while in krill a disproportionate amount of EPA and DHA is associated with phospholipids (30–65%) [89]. The interest in FODS recommendations by the American Heart Association (AHA) that promote regular consumption of fish as part of a healthy diet. [90]

The FODS products do not require clinical testing or rigorous manufacturing like prescription and over the counter preparations. This has led to concerns about the advertised content of FODS and chemical integrity of the oils found in these manufactured products [91]. Due to FDA oversight, pharmaceutical offerings have highly purified formulations of n3-FAs with highly consistent amounts of EPA and/or DHA. But in FODS, there are a plethora of oils beyond n3-FAs that may not be healthy [92]. In a typical FODS product, only one-third of the total oil content is actually n3-FAs. Patients would need to take > 10 capsules to achieve a therapeutic dose (up to 4 g/day) of mixed n3-FAs. Even more capsules would be needed to achieve adequate levels

of EPA alone. At least thirty different FAs in leading FODS have been identified and this includes many different medium and long chain saturated fatty acids, which are high in caloric content and not recommended for patients with high CV risk [92]. Primary and secondary products of oxidation were also measured in leading FODS (by sales). All of the FODS had levels of oxidized constituent products that exceeded those considered acceptable for human consumption by the US Council for Responsible Nutrition. By contrast, an n3-FA prescription product had no significant levels of oxidation products or other unhealthy oils (e.g., saturated fats).

The majority of the n3-FAs and other fatty acids used for common FODS is obtained during protein isolation from oily marine fish during industrial manufacturing of agricultural feed products [93, 94]. The n3-FAs, in particular, that are isolated during this extraction procedure are highly susceptible to oxidative damage due to multiple and conjugated unsaturated double bonds. Such fish tissue separation and oil extraction also involves exposure to very high temperatures [94]. There is also exposure to light and contaminants, leading to substantial oxidative damage to the n3-FAs and other unsaturated long chain FAs that are used in these products. In controlled experiments, such oxidative modification of these fatty acids resulted in nearly total loss of antioxidant function and other biological properties associated with its safety and mechanism of action. [95, 96]

Widely published studies from independent laboratories have confirmed these reported discrepancies in the content, purity and rancidity of FODS [92, 97•, 98, 99]. Investigations funded by the US Department of Agriculture showed that only ten out of a total 47 FODS products had accurate EPA levels based on advertised amounts [99]. Additionally, over 70% of these supplements contained less levels of total n3-FAs than promoted. A group from the University of Auckland reported that only 9% of FODS tested had n3-FA levels consistent with their labeled amounts and that the majority (80%) had elevated levels of lipid peroxides, a primary chemical product of oxidation [98]. Similar findings were reported for FODS obtained in North America with respect to lipid oxidation content and loss in biological activity [92, 100]. Together, these data indicate the unsuitability of FODS as alternatives for patients compared with direct fish intake or prescription formulations. FODS are especially inappropriate for patients at elevated CV disease risk in whom high doses of purified EPA are required for risk reduction.

### **Lipid Metabolites from Omega-3 Fatty Acids Reduce Inflammation and Promote Homeostasis**

Cells incorporate n3-FAs into phospholipids in the endoplasmic reticulum before they are incorporated into membranes during their synthesis. The ester linked n3-FAs are

especially abundant in the plasma membrane of different tissues, including retina and neuronal membranes. Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) can then release the n3-FAs from these phospholipids to be used as substrate for the generation of specialized pro-resolving mediators (SPMs) by cytoplasmic COXs, lipoxygenases (LOXs), and cytochrome P450 (CYP) [101, 102•]. Additionally, COXs, and LOXs can also produce pro-inflammatory (e.g. leukotriene B<sub>4</sub>) and anti-inflammatory (e.g. lipoxin A<sub>4</sub>) eicosanoids from n6-FAs like AA [103]. Compared with EPA, AA is more selective for COX enzymes, especially following acetylation by aspirin which yields production of specific aspirin-triggered anti-inflammatory lipoxins (ATLs) [104]. Platelet activators and other contributors to atherothrombosis like thromboxane A<sub>2</sub> also derive from n6-FAs [105]. In competing for the same COX enzymes, n3-FAs reduce pro-aggregatory thromboxanes and vasoconstrictors by producing thromboxane A<sub>3</sub> and prostaglandin I<sub>3</sub> (PGI<sub>3</sub>) [106, 107]. Prostacyclin derived from EPA, DPA and DHA specifically inhibit platelets while promoting vasodilation through endothelial-dependent NO release.

To restore homeostasis during acute and chronic disease, including atherosclerosis, the n3-FAs generate the pro-resolving mediators maresins, protectins, and resolvins, which collectively comprise the class of SPMs in macrophages and neutrophils from LOXs (we refer readers to the review by Serhan and Levy from 2018 for a comprehensive summary figure of SPMs and their synthetic pathways) [102•, 108]. Imbalances in the ratio of SPMs and pro-inflammatory lipid metabolites have been associated with unstable plaque features in human carotid endarterectomy specimens and in experimental atherosclerosis [109, 110]. SPMs resolve inflammation through a myriad of mechanisms including reducing granulocyte trafficking and cytokine generation, along with removal of cellular damage by macrophages [111, 112]. There are also changes in the balance of T helper type 1 (Th1) cell to T helper type 2 (Th2) along with polarization of CD4+ T-cells toward a Th2 identity [113–115]. The SPM family derived from EPA includes resolvin E1 (RvE1) strongly implicated in restoring tissue homeostasis. RvE1 can block T-cell activation, Th17 cell stimulation and chemotaxis, further promoting the resolution of inflammation. [116]

### **Comparative Biophysical and Antioxidant Properties of EPA and DHA**

The n3-FAs concentrate in cell membranes where they modulate structure and membrane lipid rafts while also being metabolized into various bioactive lipids within the cytoplasm. In particular, DHA has additional carbon



atoms and one double bond compared with EPA and thus generates different SPMs. The use of independent biophysical approaches recently demonstrated that EPA and DHA have opposing effects on phospholipid interactions and cholesterol distribution in isolated model membranes *in vitro*. [117••, 118••] EPA maintained intermolecular phospholipid packing constraints and preserved the even distribution of cholesterol while DHA led to disordering of membrane phospholipids, thus causing cholesterol to self-aggregate [118••, 119•]. An equimolar combination of EPA and DHA essentially eliminated their distinct effects, such that there was only a small change in membrane structure when combined [117••]. This direct biophysical evidence supports counter-regulatory actions of EPA and DHA in cell function and membrane biology.

The disparate effects of EPA and DHA on cholesterol-dependent, membrane physical properties were recently confirmed using micropipette aspiration techniques [118••]. This approach allows for the controlled application of force to the membrane surface to facilitate measurements of the apparent expansion modulus ( $K_{app}$ ), a surrogate for membrane lipid elasticity. In isolated membranes containing normal levels of cholesterol, DHA reduced the  $K_{app}$  and promoted cholesterol domain formation in membranes. By sequestering cholesterol from bulk lipid, DHA reduces van der Waals interactions between lipid constituents. As a result, DHA reduces the energy required to stretch between membrane cholesterol and phospholipid acyl chain segments. In contrast, EPA promoted an even, homogenous distribution of membrane cholesterol as characterized by a higher  $K_{app}$  value.

Fluorescence polarization techniques have substantiated the counter-regulatory effects of EPA and DHA on membrane dynamics [119•]. Changes in membrane fluidity were measured in the absence or presence of EPA and DHA by monitoring the apparent rotational correlation time (ARCT) of the molecule, 1,6-diphenyl-1,3,5-hexatriene (DPH) which is a lipophilic fluorescent probe. DHA increased the ARCT in a significant and dose-dependent manner, while EPA had no effect over a broad range (1–10 mol%) of concentrations. X-ray diffraction analysis of these same membrane preparations confirmed the presence of distinct domains enriched in cholesterol with DHA only. These data indicate that DHA, unlike EPA, promotes membrane cholesterol aggregation due to its inherent fluidizing effects. 2H NMR spectroscopy studies have shown that the same cholesterol-repelling effects with DHA due to rapid isomerizations on a nanoscale time frame [120, 121]. There are multiple examples in biology of closely related molecules having distinct physiologic actions, metabolism and tissue distributions. The sex hormones, in particular, have actions that differ dramatically despite sharing many similar chemical features.

Estradiol differs from testosterone only slightly, with one less methyl ( $\text{CH}_3$ ) group at the 19-carbon position and the carbonyl ( $\text{C}=\text{O}$ ) group at the C-3 position being reduced to an alcohol (OH).

EPA has distinct effects on membrane proteins involved in sterol transport compared to DHA, an important mechanism of atheroprotection. The contrasting effects of these n3-FAs were measured in human THP-1 macrophages. Specifically, Dakroub and colleagues measured ABCA1 transporter activity and cholesterol efflux to extracellular acceptors. This is the primary mechanism for cholesterol transfer from peripheral tissue to the liver [122]. Unlike DHA, EPA increased reverse cholesterol transport and ABCA1 activity in these cells. The actions of EPA were independent of changes in ABCA1 membrane density or cell phenotype. EPA treatment also increased the EPA/AA ratio and docosapentaenoic acid (DPA, 22:5, n3) levels unlike DHA. Similar changes in fatty acid composition, including increased EPA/AA ratio and DPA levels, were also reported with EPA treatment in human ECs. [123]

EPA and DHA have distinct tissue distributions that provide insights into difference in metabolism and function. DHA is abundant in neuronal and retinal membranes where it represents the most common polyunsaturated fatty acid and making up to half of total such lipids. In the brain, the conformational changes of DHA promote and stabilize lipid rafts enriched with cholesterol and sphingomyelin [124, 125]. The rapid motion of DHA also provides the necessary fluid environment for proteins such as rhodopsin involved in signal transduction which undergoes conformational changes during photon excitation [126]. In contrast to DHA, EPA concentrates in atherosclerotic plaque when administered at pharmacologic doses where it competes with AA for COX, thereby favoring release of certain anti-inflammatory mediators and increasing the EPA/AA ratio. [7••, 60•]

### Effects of Omega-3 Fatty Acids on Membrane Lipid Oxidation and Cholesterol Crystal Formation During Hyperglycemia

Membrane lipid peroxidation promotes cholesterol domains and reductions in its molecular width as a consequence of lipid peroxyl radicals that cause acyl chain damage and eventual cleavage [127–130]. Due to their multiple double bonds, n3-FAs can stabilize or trap free radicals in resonance structures in the hydrocarbon core where they are incorporated into membrane phospholipids. These molecules are themselves vulnerable to oxidation unless the free radicals are donated to water soluble electron acceptors like ascorbate. At elevated levels, EPA exhibited sustained antioxidant properties as evidenced by reduced lipid oxidation in various ApoB-containing lipoproteins under disease-like conditions

[119•, 131, 132•, 133]. By contrast, TG-lowering agents like fibrates, niacin and other n3-FAs had little if any activity in both lipoproteins and membranes in vitro. The radical neutralizing property of EPA depends on its five double bonds: removal of two double bonds (eicosatrienoic acid, 20:3) shows a nearly 50% reduction in antioxidant activity [132•]. Long chain fatty acids with two or fewer double bonds exhibit no antioxidant protection due to the absence of resonance stabilization properties.

EPA significantly reduced circulating levels of oxidized LDL-C as compared with placebo alone in patients with moderate or very high TGs [134]. DHA can exert some antioxidant effects, but these actions diminish with time due to the inherent rapid *trans-gauche* isomerization that leads to disruptions in adjacent acyl chains at the *sn*-1 position and inefficient inhibition of lipid peroxyl radical propagation [117••, 120, 132•, 135–137]. The antioxidant effects of EPA increase when combined with the atorvastatin active metabolite, which occupies a common membrane location to facilitate further resonance stabilization of reactive oxygen species (ROS) through its aromatic ring structures embedded in the membrane lipid bilayer. [127, 133, 138, 139]

The lipid antioxidant effects of EPA were also observed in membranes under disease-like conditions of hyperglycemia. High glucose levels independently increase ROS production and the formation of carbonyl species and other oxidation products associated with lipid degradation [129, 131]. Such effects promote discrete changes in lipid order and structural properties that are manifested by increased cell permeability and loss of barrier integrity [14, 140]. Prolonged exposure to elevated glucose also promotes membrane cholesterol domain formation that precipitate extracellular crystals and


their eventual deposition in the necrotic core of the atheroma [129, 131]. The ability of glucose to promote lipid oxidation and cholesterol crystals appear selective, as other monosaccharides (e.g., mannose) at comparable concentrations do not reproduce these pathologic changes. Glucose reacts directly with singlet oxygen to form glucose radicals and other oxygen radical species [141, 142]. Under these conditions, EPA inhibited glucose-induced changes, including cholesterol crystals, in a concentration-dependent manner (Fig. 2). [131] The atorvastatin active metabolite also blocks lipid oxidation and cholesterol crystal biogenesis under hyperglycemic conditions that complements these actions of EPA. [127]

Cholesterol crystals also induce formation of neutrophil extracellular traps (NETs) in a manner dependent on oxygen radicals. NETs amplify and propagate thrombi in the arterial wall [143]. NETs also release mature IL-1 $\beta$  through NLRP3 inflammasome stimulation [144]. IL-1 $\alpha$  associated with NETs also activates vascular endothelium [145]. NETs localize in lesions and genetic deletion of key NET production enzymes in ApoE-deficient mice exposed to a high-fat diet can reduce atherosclerosis to an extent similar to that observed in NLRP3-specific knockout animals [144]. This evidence strengthens the relationship or connection between cholesterol crystals and NLRP3-dependent inflammatory signaling within the advanced atheroma (Fig. 3).

## Omega-3 Fatty Acids and Statins Influence Endothelial Function

Impaired endothelium can promote the entry and retention of ApoB-containing lipoproteins in the arterial intima, triggering macrophage- and T cell-mediated inflammatory

**Fig. 2** EPA incorporates into phospholipids of membrane bilayers and interrupts the propagation of oxygen free radicals and prevents cholesterol domain formation. Circulating EPA enters cells and is esterified during the biosynthesis of membrane phospholipids. Following incorporation into plasma membrane, EPA has a stable, extended conformation within the membrane that inhibits the propagation of lipid peroxyl radicals and consequent cholesterol crystal formation




changes [146]. LDL-C modification or oxidation results in deamination of lysine residues on ApoB and formation of reactive aldehydes that are pro-inflammatory. Scavenger receptors on macrophages bind modified LDL, mediating its uptake and foam cell formation in the atheroma [147]. Activated macrophages sustain a local inflammatory reaction through release of cytokines and other signaling molecules [148, 149]. Increased risk for acute coronary and ischemic events as well as metabolic diseases are positively associated with levels of oxidized forms of circulating LDL [150–153]. Oxidized LDL-C also shifts endothelial conditions away from an anti-inflammatory and anti-thrombotic state as evidenced by increased production of pro-thrombotic mediators and vasoconstrictors, including endothelin-1, thromboxane A2 and prostaglandin H2.

Loss of endothelial function is a hallmark feature of atherothrombotic disease, leading to increased CV risk [154–156]. EC dysfunction begins with the fatty streak and incorporation of Apo B-containing particles such as LDL-C and, to a lesser extent, TGRLs, in the intima. Although they

enter the intimal space at a lower rate, TGRLs efflux from the arterial wall at approximately 20-fold less than the rate of LDL-C, greatly increasing the exposure to oxidative damage and glycation to aggravate EC dysfunction [157]. Activated ECs express adhesion molecules promoting leukocyte (e.g, monocyte) attachment and transendothelial migration. These ECs also recruit immune cells including T cells and dendritic cells. The monocytes in the intima scavenge modified LDL-C and Apo E remnants. The activated macrophages not only promote inflammation, but also contribute to the plaque volume composed of cholesterol crystals, cholesteryl esters and cellular debris resulting from abnormal efferocytosis (clearance of dead cells.)

Additionally, ECs challenged with TNF- $\alpha$  and incubated with serum from subjects administered 4 g/d EPA had reduced expression of inflammatory biomarkers. The reductions in inflammatory signaling molecules were not reproduced in these human cells with serum from DHA-treated subjects [158]. In isolated arterial segments, EPA also reversed EC dysfunction under conditions of atherosclerosis with a statin [159]. The



**Fig. 3** Cholesterol crystals can activate the NLRP3 inflammasome, leading to increased IL-1 $\beta$  release. Cholesterol crystals can enter cells via phagocytosis destined for lysosomal degradation. However, this process can cause lysosomal rupture and release of proteolytic contents into the cytosol (including cathepsin B and L). This leads to assembly of the (NOD-LLR and pyrin domain-containing

protein 3 (NLRP3) inflammasome. NLRP3 recruits NIMA-related kinase 7 (NEK7), the adapted apoptosis-associated speck-like protein containing a caspase (ASC), and procaspase-1, which is then converted into activated caspase-1 which, in turn, converts the inactive pro-forms of interleukins (IL)-1 $\beta$  and IL-18 to their mature biologically functional forms for release


combination of EPA with a statin enhanced bioavailability of NO concomitant with reductions in nitroxidative stress, including peroxynitrite ( $\text{ONOO}^-$ ) generation. The comparative effects of n3-FAs were also evaluated in human ECs without exogenous challenges, in which EPA treatment improved the NO/ $\text{ONOO}^-$  release ratio and eNOS coupling efficiency. By contrast, neither DHA nor AA improved eNOS function under similar conditions [123]. These effects of EPA could be related to changes in total cellular fatty acid composition following treatment. Specifically, EPA treatment markedly increased levels of EPA and its immediate metabolic product, DPA, with no such changes in levels of DHA or AA in vitro. This resulted in a tenfold increase in the EPA/AA ratio, a predictor of CV risk and outcomes. Indeed, circulating EPA levels independently predicted event reduction in REDUCE-IT compared to other traditional risk factors like LDL-C and non-HDL. [55]

## Conclusion

Among patients with metabolic disorders and CV disease, there remains residual risk despite effective oral and non-oral treatments that effectively lower LDL-C. Considerable evidence points to causality of TGRL in atherothrombosis, but risk reduction with strategies that reduce these lipids remain elusive. Despite pronounced

reductions in TG levels, fibrates and the selective PPAR alpha modulator pemafibrate, along with various n3-FA formulations, did not reduce events in high-risk patients. However, two trials with EPA only formulations (i.e., IPE) showed reductions in CV events beyond TG lowering. These findings support a broad panel of pleiotropic actions as discussed above that associate with on-treatment EPA levels in REDUCE-IT that interfere with the CV disease continuum (Fig. 4). While not fully elucidated, these mechanisms of action for EPA include inhibition of thrombosis and platelet activation as well as preserved membrane structure, EC function, cholesterol distribution in the cell membrane and enhanced cholesterol efflux compared to DHA. In patients with atherosclerotic disease, EPA reduced plaque volume while increasing fibrous cap thickness when compared with statin treatment alone. As indicated by its abundance, DHA has critical roles in the functions of the central nervous system and retina, yet it may have limited effects on human atherothrombosis under the conditions studied. DHA containing formulations did not reproduce many of the benefits of IPE administration, likely related to differences in physicochemical properties, tissue distribution, and metabolism, or even by opposing certain mechanisms of EPA. Additional investigations into the molecular mechanism of action for EPA may yield new insights into the etiology and treatment of atherosclerosis.

**Fig. 4** IPE interrupts the cardiovascular disease continuum at multiple points through broad pleiotropic mechanisms. The cardiovascular disease continuum progresses from early endothelial dysfunction and dyslipidemia to vascular inflammation that culminates in atherothrombotic events, target organ damage, and death. The REDUCE-IT trial indicated that icosapent ethyl (IPE) treatment reduced a broad range of cardiovascular events by 25%. The active ingredient of IPE, EPA, may interrupt the cardiovascular continuum at several points, to limit overall risk



**Acknowledgements** We thank Luke Groothoff, Elucida Research, for preparing artwork for the figures.

**Data Availability** Data sharing not applicable to this article as no datasets were generated or analyzed in the current manuscript.

## Declarations

**Conflict of Interest** RPM received grant/research support from Amarin Pharma Inc., Esperion Therapeutics, HLS Therapeutics, Lexicon and the Cleveland Clinic.

PL is an unpaid consultant to or is involved in clinical trials for Amgen, AstraZeneca, the Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron; is a member of the scientific advisory boards of Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, TenSixteen Bio, and XBiotech; has received research funding to his laboratory in the past 2 years from Novartis; he is on the board of directors of XBiotech; Libby has a financial interest in XBiotech, a company developing therapeutic human antibodies; and has a financial interest in TenSixteen Bio, a company targeting somatic mosaicism and CHIP to discover and develop novel therapeutics to treat age-related diseases. Dr Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.

MB received grant support from Amarin Pharma, Inc.

DLB discloses the following relationships—Advisory Board: AngioWave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: AngioWave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler,

Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent.) Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda.

SCRS has an employment relationship with Elucida Research LLC.

**Human and Animal Rights and Informed Consent** All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Khan T. World Health Organization - Cardiovascular Diseases Overview. 2022.
2. Ganda OP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. *J Am Coll Cardiol*. 2018;72:330–43.
3. Libby P. Triglycerides on the rise: should we swap seats on the seesaw? *Eur Heart J*. 2014;36:774–6.

- 4.● Tall AR, et al. Addressing dyslipidemic risk beyond LDL-cholesterol. *The Journal of Clinical Investigation*. 2022;132. **(This review covers residual cardiovascular risk and the role triglycerides play, including current and novel therapies targeting triglycerides for event reduction.)**
5. Collaboration\* TERF. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. *JAMA*. 2009;302:1993–2000.
6. Triglyceride-mediated pathways and coronary disease. collaborative analysis of 101 studies. *The Lancet*. 2010;375:1634–9.
- 7.●● Mason RP, et al. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. *Arterioscler Thromb Vasc Biol*. 2020;40:1135–47. **(This review covers many of the biochemical differences between EPA and DHA and provides mechanistic insight into potential novel mechanisms of atheroprotection with EPA.)**
8. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. *Circ Res*. 2016;118:547–63.
9. Burgess S, et al. Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions. *PLoS ONE*. 2014;9:e108891.
10. Ference BA, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. *JAMA*. 2019;321:364–73.
11. Hansen SEJ, et al. Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. *Clin Chem*. 2019;65:321–32.
12. Mason RP, et al. Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction. *Metabolism - Clinical and Experimental*. 2022;130.
13. Mason RP, Eckel RH. Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction. *Am J Med*. 2021;134:1085–90.
14. Borow KM, et al. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. *Atherosclerosis*. 2015;242:357–66.
15. Sherratt SCR, et al. A Biological Rationale for the Disparate Effects of Omega-3 Fatty Acids on Cardiovascular Disease Outcomes. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2022;102450.
16. Laufs U, et al. Clinical review on triglycerides. *Eur Heart J*. 2019;41:99–109c.
17. Vallejo-Vaz AJ, et al. Triglycerides and residual risk. *Curr Opin Endocrinol Diabetes Obes*. 2020;27:95–103.
18. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. *New England Journal of Medicine*. 2014;371:22–31.
19. Bergmark BA, et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. *Circulation*. 2022;145:1377–86.
20. Ionis Pharmaceuticals I. Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. 2022.
21. Raal FJ, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020;383:711–20.
22. Rosenson RS, et al. Evinacumab in Patients with Refractory Hypercholesterolemia. *N Engl J Med*. 2020;383:2307–19.
23. Witztum JL, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *N Engl J Med*. 2019;381:531–42.
24. Onat UI, et al. Intercepting the Lipid-Induced Integrated Stress Response Reduces Atherosclerosis. *J Am Coll Cardiol*. 2019;73:1149–69.
25. Zhao N, et al. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors. *J Autoimmun*. 2020;113:102515.
26. Martínez GJ, et al. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. *Atherosclerosis*. 2018;269:262–71.
- 27.● Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature*. 2010;464:1357–61. **(This study was the first to show direct evidence that the NLRP3 inflammasome can be activated by cholesterol crystals.)**
28. Ballantyne CM, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. *J Clin Lipidol*. 2016;10:635–645.e1.
29. Effects of combination lipid therapy in type 2 diabetes mellitus. *New England Journal of Medicine*. 2010;362:1563–1574.
30. Effects of extended-release niacin with laropirant in high-risk patients. *New England Journal of Medicine*. 2014;371:203–212.
31. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *New England Journal of Medicine*. 2011;365:2255–2267.
32. Pradhan AD, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. *Am Heart J*. 2018;206:80–93.
33. Kowa Research Institute I. Kowa to discontinue K-877 (pemafibrate) "PROMINENT" cardiovascular outcomes study. 2022.
34. Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. *Lipids Health Dis*. 2017;16:149.
35. Shearer GC, et al. Fish oil — How does it reduce plasma triglycerides? *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. 2012;1821:843–51.
36. Oh DY, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*. 2010;142:687–98.
37. Quesada-López T, et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. *Nat Commun*. 2016;7:13479.
38. Gotoh C, et al. The regulation of adipogenesis through GPR120. *Biochem Biophys Res Commun*. 2007;354:591–7.
39. Xu HE, et al. Molecular Recognition of Fatty Acids by Peroxisome Proliferator-Activated Receptors. *Mol Cell*. 1999;3:397–403.
40. Dubois V, et al. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. *J Clin Invest*. 2017;127:1202–14.
41. Schoonjans K, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. *EMBO J*. 1996;15:5336–48.
42. Grevengoed TJ, et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. *The Journal of Clinical Investigation*. 2021;131.
- 43.●● Bhatt D, L., et al. Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia. *New England Journal of Medicine*. 2019;380:11–22. **(This is the original data manuscript of REDUCE-IT describing significant cardiovascular event reduction with icosapent ethyl.)**
44. Olshansky B, et al. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. *Eur Heart J - Cardiovasc Pharm*. 2020;7:e61–3.
45. Peterson BE, et al. Reduction in Revascularization With Icosapent Ethyl. *Circulation*. 2021;143:33–44.
46. Bhatt DL, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. *J Am Coll Cardiol*. 2019;73:2791–802.
47. Peterson BE, et al. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary

- intervention- insights from REDUCE-IT PCI. *J Am Heart Assoc.* 2022;11:e022937.
48. Gaba P, et al. Prevention of ischemic events and mortality with icosapent ethyl in patients with prior myocardial infarction. *Journal of the American College of Cardiology.* 2022;In Press.
  49. Verma S, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. *Circulation.* 2021;144:1845–55.
  50. Majithia A, et al. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. *Circulation.* 2021;144:1750–9.
  51. Singh N, et al. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. *J Am Coll Cardiol.* 2022;79:220–2.
  52. Bhatt DL, et al. REDUCE-IT USA. *Circulation.* 2020;141:367–75.
  - 53.● Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *The Lancet.* 2007;369:1090–8. **(This is the original data manuscript of the JELIS trial, which showed significant cardiovascular event reduction in hypercholesterolemic patients with EPA ethyl ester added to statin therapy.)**
  54. Saito Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis.* 2008;200:135–40.
  55. Pisaniello AD, et al. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. *European Medical Journal.* 2020;5:29–36.
  56. Watanabe T, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. *J Cardiol.* 2017;70:537–44.
  57. Nishio R, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. *Atherosclerosis.* 2014;234:114–9.
  - 58.● Budoff MJ, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. *Eur Heart J.* 2020;41:3925–32. **(The EVAPORATE trial provides mechanistic insight into the benefits of icosapent ethyl on atherosclerotic cardiovascular events, where plaque volume not only attenuated by also regressed.)**
  59. Williams MC, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction. *Circulation.* 2020;141:1452–62.
  - 60.● Sato T, et al. Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques. *Arterioscler Thromb Vasc Biol.* 2019;39:1802–16. **(This study showed that EPA preferentially incorporates into atherosclerotic plaques compared to DHA and other novel mechanisms of atheroprotection with EPA.)**
  61. Cawood AL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. *Atherosclerosis.* 2010;212:252–9.
  - 62.● Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. *JAMA.* 2020;324:2268–80. **(The original data manuscript of the STRENGTH trial, showing no reduction of cardiovascular events with an EPA/DHA mixed formulation in a similar patient population as REDUCE-IT.)**
  63. Effects of n–3 Fatty Acid Supplements in Diabetes Mellitus. *New England Journal of Medicine.* 2018;379:1540–1550.
  64. Manson JE, et al. Marine n–3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. *N Engl J Med.* 2018;380:23–32.
  - 65.● Aung T, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology.* 2018;3:225–33. **(This meta analysis, performed in 2018 prior to the REDUCE-IT and STRENGTH trials, showed no significant benefit with omega-3 fatty acid supplementation on cardiovascular disease events.)**
  66. Abdelhamid AS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews.* 2020.
  67. Kwak SM, et al. Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials Archives of Internal Medicine. 2012;172:686–94.
  68. Rizos EC, et al. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis. *JAMA.* 2012;308:1024–33.
  69. Nissen SE, et al. Association Between Achieved  $\omega$ -3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. *JAMA Cardiology.* 2021;6:910–7.
  70. Kapoor K, et al. Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. *J Clin Lipidol.* 2021;15:545–55.
  71. Kalstad AA, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. *Circulation.* 2021;143:528–39.
  72. Myhre P, et al. Changes in EPA and DHA during supplementation with omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial. *European Heart Journal.* 2021;42.
  73. Ridker PM, et al. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 $\beta$ , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. *Circulation.* 2022;0:<https://doi.org/10.1161/CIRCULATIONAHA.122.059410>.
  74. Ridker PM, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. *N Engl J Med.* 2018;380:752–62.
  75. Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. *N Engl J Med.* 2008;359:2195–207.
  76. Olshansky B, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. *Eur Heart J Suppl.* 2020;22:J34–48.
  77. Gopaul VS, et al. Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. *Eur J Pharm Sci.* 2021;161:105776.
  78. FDA. Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document. 2019.
  79. Lakshmanan S, et al. Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. *Cardiovasc Res.* 2019;116:479–82.
  80. Bhatt DL, et al. A Revolution in Omega-3 Fatty Acid Research\*. *J Am Coll Cardiol.* 2020;76:2098–101.
  81. Shahidi F, Ambigaipalan P. Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. *Annu Rev Food Sci Technol.* 2018;9:345–81.

82. Burdge GC, et al. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [<sup>13</sup>C]  $\alpha$ -linolenic acid to longer-chain fatty acids and partitioning towards  $\beta$ -oxidation in older men. *Br J Nutr.* 2003;90:311–21.
83. Giltay EJ, et al. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. *Am J Clin Nutr.* 2004;80:1167–74.
84. Otto SJ, et al. Changes in the maternal essential fatty acid profile during early pregnancy and the relation of the profile to diet. *Am J Clin Nutr.* 2001;73:302–7.
85. Bergé J-P, Barnathan G. Fatty Acids from Lipids of Marine Organisms: Molecular Biodiversity, Roles as Biomarkers, Biologically Active Compounds, and Economical Aspects. In: Ulber R, Le Gal Y, editors. *Marine Biotechnology I* Berlin. Heidelberg: Springer, Berlin Heidelberg; 2005. p. 49–125.
86. Rørå AMB, et al. Influence of high content of dietary soybean oil on quality of large fresh, smoked and frozen Atlantic salmon (*Salmo salar*). *Aquacult Int.* 2005;13:217–31.
87. Torstensen BE, et al. Tailoring of Atlantic Salmon (*Salmo salar* L) Flesh Lipid Composition and Sensory Quality by Replacing Fish Oil with a Vegetable Oil Blend. *J Agri Food Chem.* 2005;53:10166–78.
88. Barnes PM, et al. Complementary and alternative medicine use among adults and children: United States. *Natl Health Stat Rep.* 2007;2008:1–23.
89. Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. *Prostaglandins Leukot Essent Fatty Acids.* 2013;89:1–8.
90. Rimm EB, et al. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. *Circulation.* 2018;138:e35–47.
91. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. *Manag Care.* 2016;25:46–52.
92. Mason RP, Sherratt SC. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. *Biochem Biophys Res Commun.* 2017;483:425–9.
93. Sullivan JC, et al. Modeling the primary oxidation in commercial fish oil preparations. *Lipids.* 2011;46:87–93.
94. Turner R, et al. Are the health benefits of fish oils limited by products of oxidation? *Nutr Res Rev.* 2006;19:53–62.
95. Garcia-Hernandez VM, et al. Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. *Int J Food Sci Nutr.* 2013;64:993–1000.
96. Nogueira MS, et al. Effect of long-term ingestion of weakly oxidised flaxseed oil on biomarkers of oxidative stress in LDL-receptor knockout mice. *Br J Nutr.* 2016;116:258–69.
- 97.● Albert BB, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. *Scientific Reports.* 2015;5. **(Comprehensive study of omega-3 fatty acid supplement integrity in New Zealand, showing inconsistencies between products and other concerning aspects.)**
98. Albert BB, et al. Oxidation of marine omega-3 supplements and human health. *Biomed Res Int.* 2013;2013:1–8.
99. Kleiner AC, et al. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. *J Sci Food Agric.* 2015;95:1260–7.
100. Ritter JC, et al. Quality analysis of commercial fish oil preparations. *J Sci Food Agric.* 2013;93:1935–9.
101. O'Connell TD, et al. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. *Eur Heart J Suppl.* 2020;22:J3-j20.
- 102.● Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *J Clin Investig.* 2018;128:2657–69. **(An excellent review from Dr. Serhan who has been intimately involved in the discovery of specialized pro-resolving mediators and their role in inflammation.)**
103. Bonafini S, Fava C. Omega-3 fatty acids and cytochrome P450-derived eicosanoids in cardiovascular diseases: Which actions and interactions modulate hemodynamics? *Prostaglandins Other Lipid Mediat.* 2017;128–129:34–42.
104. Wada M, et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived *versus* eicosapentaenoic acid-derived substrates and products. *J Biol Chem.* 2007;282:22254–66.
105. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. *Br J Pharmacol.* 2019;176:1038–50.
106. Arterburn LM, et al. Distribution, interconversion, and dose response of n–3 fatty acids in humans. *Am J Clin Nutr.* 2006;83:1467S–1476S.
107. Braeckman RA, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). *Prostaglandins Leukot Essent Fatty Acids.* 2013;89:195–201.
108. Larsson SC, et al. Dietary long-chain n–3 fatty acids for the prevention of cancer: a review of potential mechanisms. *Am J Clin Nutr.* 2004;79:935–45.
109. Fredman G, et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. *Nat Commun.* 2016;7:12859.
110. Viola JR, et al. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprotection in Mice. *Circ Res.* 2016;119:1030–8.
111. Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. *Am J Pathol.* 2017;187:1211–21.
112. Gabbs M, et al. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. *Adv Nutr.* 2015;6:513–40.
113. Zhang P, et al. Dietary (n-3) Polyunsaturated Fatty Acids Modulate Murine Th1/Th2 Balance toward the Th2 Pole by Suppression of Th1 Development. *J Nutr.* 2005;135:1745–51.
114. Monk JM, et al. n3 PUFAs Reduce Mouse CD4+ T-Cell Ex Vivo Polarization into Th17 Cells. *J Nutr.* 2013;143:1501–8.
115. Monk JM, et al. Dietary n-3 Polyunsaturated Fatty Acids (PUFA) Decrease Obesity-Associated Th17 Cell-Mediated Inflammation during Colitis. *PLoS ONE.* 2012;7:e49739.
116. Oner F, et al. Resolvin E1 Regulates Th17 Function and T Cell Activation. *Frontiers in Immunology.* 2021;12.
- 117.●● Sherratt SCR, et al. EPA and DHA containing phospholipids have contrasting effects on membrane structure. *Journal of Lipid Research.* 2021;62. **(A biophysical analysis comparing EPA and DHA linked in phospholipids, showing distinct effects of EPA and DHA on electron density distribution and localization of these fatty acyl chains. When combined, their separate effects were attenuated.)**
- 118.●● Jacobs ML, et al. EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol. *Biophys J.* 2021;120:2317–29. **(A biophysical study showing, once again, distinct effects of EPA and DHA on cholesterol distribution and membrane elasticity.)**
- 119.● Mason RP, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. *Biochem Biophys Acta.* 2016;1858:3131–40. **(A third biophysical study showing distinct effects of EPA and DHA on membrane fluidity and cholesterol distribution.)**
120. Soubias O, Gawrisch K. Docosahexaenoyl chains isomerize on the sub-nanosecond time scale. *J Am Chem Soc.* 2007;129:6678–9.



121. Soni SP, et al. Docosahexaenoic acid enhances segregation of lipids between raft and nonraft domains:  $^2\text{H}$ -NMR Study. *Biophys J*. 2008;95:203–14.
122. Dakroub H, et al. Eicosapentaenoic acid membrane incorporation stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages. *Biochimica et Biophysica Acta (BBA) - Mole Cell Biol Lipids*. 2021;1866:159016.
123. Sherratt SCR, et al. Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2021;173.
124. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. *Frontiers in Aging Neuroscience*. 2015;7.
125. Innis SM. Dietary (n-3) Fatty Acids and Brain Development. *J Nutr*. 2007;137:855–9.
126. Querques G, et al. Retina and Omega-3. *J Nutri Meta*. 2011;2011:748361.
127. Mason RP, et al. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. *J Biol Chem*. 2006;281:9337–45.
128. Mason RP, et al. Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis. *Free Radical Biol Med*. 1997;23:419–25.
129. Self-Medlin Y, et al. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. *Biochem Biophys Acta*. 2009;1788:1398–403.
130. Wratten ML, et al. Structural and dynamic effects of oxidatively modified phospholipids in unsaturated lipid membranes. *Biochemistry*. 1992;31:10901–7.
131. Mason RP and Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. *Biochimica et Biophysica Acta*. 2015;1848.
132. Sherratt SCR, et al. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. *Biochimica et Biophysica Acta - Biomembranes*. 2020;1862. **(An in vitro study showing unique antioxidant effects of EPA compared to other fatty acids in multiple models of atherosclerosis.)**
133. Mason RP, et al. Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. *J Cardiovasc Pharmacol*. 2016;68:33–40.
134. Bays HE, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. *Am J Cardiovasc Drugs*. 2013;13:37–46.
135. Williams Justin A, et al. Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains. *Biophys J*. 2012;103:228–37.
136. Shaikh SR, et al. How polyunsaturated fatty acids modify molecular organization in membranes: insight from NMR studies of model systems. *Biochem Biophys Acta*. 2015;1848:211–9.
137. Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. *J Nutr Biochem*. 2012;23:101–5.
138. Jacob R, et al. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. *J Cardiovasc Pharmacol*. 2013;62:160–6.
139. Aviram M, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. *Atherosclerosis*. 1998;138:271–80.
140. Mason RP, Jacob RF. Membrane microdomains and vascular biology: emerging role in atherogenesis. *Circulation*. 2003;107:2270–3.
141. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. *Physiol Res*. 2004;53:131–42.
142. Pennathur S, Heinecke JW. Mechanisms for Oxidative Stress in Diabetic Cardiovascular Disease. *Antioxid Redox Signal*. 2007;9:955–69.
143. Döring Y, et al. Neutrophils in Atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2015;35:288–95.
144. Warnatsch A, et al. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. *Science*. 2015;349:316–20.
145. Folco EJ, et al. Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1 $\alpha$  and Cathepsin G. *Arterioscler Thromb Vasc Biol*. 2018;38:1901–12.
146. Gimbrone MA, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. *Circ Res*. 2016;118:620–36.
147. Steinberg D, Witztum JL. Oxidized Low-Density Lipoprotein and Atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2010;30:2311–6.
148. Libby P. The changing landscape of atherosclerosis. *Nature*. 2021;592:524–33.
149. Libby P, et al. Progress and challenges in translating the biology of atherosclerosis. *Nature*. 2011;473:317–25.
150. Ehara S, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. *Circulation*. 2001;103:1955–60.
151. Walter MF, et al. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. *J Am Coll Cardiol*. 2008;51:1196–202.
152. Walter MF, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study. *J Am Coll Cardiol*. 2004;44:1996–2002.
153. Holvoet P, et al. The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort. *Diabetes*. 2004;53:1068–73.
154. Ignarro LJ, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci USA*. 1987;84:9265–9.
155. Rees DD, et al. Role of endothelium-derived nitric oxide in the regulation of blood pressure. *Proc Natl Acad Sci USA*. 1989;86:3375–8.
156. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. *Cardiovasc Res*. 1999;43:562–71.
157. Proctor SD, et al. Arterial Permeability and Efflux of Apolipoprotein B-Containing Lipoproteins Assessed by In Situ Perfusion and Three-Dimensional Quantitative Confocal Microscopy. *Arterioscler Thromb Vasc Biol*. 2004;24:2162–7.
158. Pisaniello AD, et al. Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. *Atherosclerosis*. 2021;324:27–37.
159. Mason RP, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. *Biomed Pharmacother*. 2018;103:1231–7.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.